SOUTHLAKE, Texas--(BUSINESS WIRE)--TearLab® Corporation, the global leader in ophthalmic point-of-care diagnostics, announced today that it will be expanding its position in corneal health under the new name Trukera™ Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health.
“We continue to remain dedicated to the advancement of corneal health. Our decision to rebrand as Trukera Medical represents our history as pioneers of point-of-care testing for corneal disease, while also more clearly reflecting where we’re going next,” said Trukera Medical CEO Adam Szaronos. “We expect to see strong continued growth ahead with point-of-care diagnostics, driven primarily by practices specializing in cornea and premium cataract/refractive surgery. This is where the physician and patient need is greatest for advanced corneal health, and it’s where we find additional unmet needs that we are positioned to address for our customers. Our vision is to be the world’s leading and most trusted corneal health company for providers and patients, and the leadership team and I are excited to introduce a name that represents this expanded vision.”
TearLab introduced osmolarity testing as an innovative, objective diagnostic tool in the eye care market with the TearLab Osmolarity System in 2010. The device has since become a routine and even essential part of eye care, with over 24 million tests completed worldwide. Doctors have come to rely on the objective clinical data from this 90-second test to help them make informed decisions about dry eye disease, and the ASCRS OSD Algorithm deemed osmolarity an “essential” preoperative diagnostic test for cataract and refractive surgeries.1 It will remain a flagship device in the Trukera Medical portfolio.
“Corneal health is an exciting focus for us because precise, predictive and practical corneal evaluation can inform treatment in all aspects of ocular health,” explained James V. Mazzo, Executive Chairman of the Board at Trukera Medical. “Customers have expanded the use of osmolarity testing from aiding in the diagnosis and management of corneal disease to ensuring risk factors are identified for minimizing refractive surprises after surgery. As Trukera, we’re looking forward to helping improve patients’ lives even further by advancing doctors’ capabilities around corneal health.”
The first new product under the Trukera Medical brand will be announced later this month and launched at the upcoming World Cornea Congress and American Academy of Ophthalmology. To learn more and get the latest news, visit www.TearLab.com.
1. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019 May;45(5):669-684. doi: 10.1016/j.jcrs.2019.03.023. |
About Trukera Medical
Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera’s expanding portfolio continues to focus on improving corneal health, both as a primary goal and in preparation for surgery. Get more details and new product announcements at www.TearLab.com.
